(Q35609532)

9 August 2017

1 reference

title

Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy (English)

1 reference

9 August 2017

1 reference

Edward M Messing

1

1 reference

PubMed ID

14680308

9 August 2017

Ian Thompson

series ordinal

2

1 reference

9 August 2017

1 November 2003

1 reference

Urologic Clinics of North America

9 August 2017

1 reference

9 August 2017

30

1 reference

9 August 2017

4

1 reference

9 August 2017

687-702, viii

1 reference

Quality of life after radical prostatectomy or watchful waiting.

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Deferred treatment in clinically localised prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Expectant management of localized prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

High 10-year survival rate in patients with early, untreated prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Watchful waiting for early stage prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Re: Long-term survival and mortality in prostate cancer treated with noncurative intent

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Active monitoring (deferred treatment or watchful waiting) in the treatment of prostate cancer. A review.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Levels of prostate specific antigen that predict skeletal spread in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Green tea and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Prostate cancer and selenium

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

The role of soy phytoestrogens in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Tomato products, lycopene, and prostate cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Vitamin E and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Vitamin D and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Lifestyle/dietary supplement partial androgen suppression and/or estrogen manipulation. A novel PSA reducer and preventive/treatment option for prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Prevalence of complementary medicine in urologic practice. A review of recent studies with emphasis on use among prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Watchful waiting as a treatment option for localized prostate cancer in the PSA era.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

The role of serial transrectal ultrasonography in a 'watchful waiting' protocol for men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Metastatic Carcinoma of the Prostate: Identifying Prognostic Groups Using Recursive Partitioning

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Medical complications and outcomes after hip fracture repair

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Survival and potential years of life lost after hip fracture in men and age-matched women

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Strength is a major factor in balance, gait, and the occurrence of falls

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Effects of human growth hormone in men over 60 years old

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Pain management services in palliative care: a national survey

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

Educational interventions to improve cancer pain control: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2803%2900050-8

7 January 2021

10.1016/S0094-0143(03)00050-8

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14680308